• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-1/A filed by CG Oncology Inc.

    12/11/24 4:09:22 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGON alert in real time by email
    S-1/A 1 d872865ds1a.htm S-1/A S-1/A

    As filed with the Securities and Exchange Commission on December 11, 2024.

    Registration No. 333-283725

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    AMENDMENT NO. 1 TO

    FORM S-1

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    CG ONCOLOGY, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   2836   37-1611499

    (State or other jurisdiction of

    incorporation or organization)

     

    (Primary Standard Industrial

    Classification Code Number)

     

    (I.R.S. Employer

    Identification No.)

    400 Spectrum Center Drive, Suite 2040

    Irvine, CA 92618

    (949) 409-3700

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Arthur Kuan

    Chief Executive Officer

    400 Spectrum Center Drive, Suite 2040

    Irvine, CA 92618

    (949) 409-3700

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Divakar Gupta

    Charles S. Kim

    Milson C. Yu

    Cooley LLP

    55 Hudson Yards

    New York, NY 10001

    (212) 479-6000

     

    Joshua F. Patterson

    General Counsel &

    Chief Compliance Officer

    400 Spectrum Center Drive,

    Suite 2040

    Irvine, CA 92618

    (949) 409-3700

     

    Matthew T. Bush

    Cheston J. Larson

    Anthony Gostanian

    Latham & Watkins LLP

    12670 High Bluff Drive

    San Diego, CA 92130

    (858) 523-5400

     

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement is declared effective.

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐   Non-accelerated filer ☒   Smaller reporting company ☒

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

    The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

     

     

     


    Explanatory Note

    CG Oncology, Inc. is filing this Amendment No. 1 (this “Amendment”) to its Registration Statement on Form S-1 (“Registration Statement”) for the purpose of filing Exhibits 1.1 and 5.1. This Amendment does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly, such prospectus has been omitted.


    PART II

    INFORMATION NOT REQUIRED IN PROSPECTUS

    Item 13. Other Expenses of Issuance and Distribution.

    The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission (SEC) registration fee and the Financial Industry Regulatory Authority, Inc. (FINRA) filing fee.

     

         Amount Paid or
    to Be Paid
     

    SEC registration fee

       $ 47,468  

    FINRA filing fee

       $ 47,006  

    Accountants’ fees and expenses

       $ 250,000  

    Legal fees and expenses

       $ 250,000  

    Transfer Agent’s fees and expenses

       $ 10,000  

    Printing expenses

       $ 50,000  

    Miscellaneous expenses

       $ 15,526  
      

     

     

     

    Total expenses

       $ 670,000  
      

     

     

     

    Item 14. Indemnification of Directors and Officers.

    Section 102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides that no director of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General Corporation Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

    Section 145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

    Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or

     

    II-1


    she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.

    We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request.

    We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.

    In any underwriting agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act, against certain liabilities.

    Item 15. Recent Sales of Unregistered Securities.

    Set forth below is information regarding unregistered securities issued by us since December 1, 2021 to the date of this registration statement. Also included is the consideration received by us for such securities and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed.

     

      (a)  

    Issuances of Securities

     

      1.

    In September 2022 and October 2022, we issued to investors an aggregate of 112,422,700 shares of Series E redeemable convertible preferred stock at a purchase price of $1.0674 per share, for aggregate consideration of approximately $120 million.

     

      2.

    In July 2023, we issued to investors an aggregate of 81,587,937 shares of Series F redeemable convertible preferred stock at a purchase price of $1.2872 per share, for aggregate consideration of approximately $105 million.

    No underwriters were involved in the foregoing issuances of securities. The securities described in this section (a) of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder, for transactions by an issuer not involving any public offering, and to the extent an exemption from such registration was required. All holders of securities described above represented to us in connection with their purchase or issuance that they were accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time. The holders received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration.

     

      (b)  

    Grants of Stock Options

     

      1.

    From December 1, 2021 through the date of this registration statement, we granted stock options to purchase an aggregate of 6,528,543 shares of our common stock at a weighted-average exercise

     

    II-2


     

    price of $14.57 per share, to certain of our employees, consultants and directors in connection with services provided to us by such persons. 375,471 of these options have been exercised and 349,096 have been cancelled, forfeited and expired through the date of this registration statement.

    The stock options and common stock issuable upon exercise of such options as described in this section (b) of Item 15 were issued pursuant to written compensatory plans or arrangements with our employees and directors, in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 701 promulgated under the Securities Act or the exemption set forth in Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not involving any public offering. All recipients either received adequate information about us or had access, through employment or other relationships, to such information.

     

      (c)  

    Automatic Conversion of Preferred Stock

    On January 29, 2024, upon the closing of our initial public offering, all shares of outstanding redeemable convertible preferred stock automatically converted into 38,413,913 shares of our common stock. The issuance of such shares of common stock was exempt from the registration requirements of the Securities Act, pursuant to Section 3(a)(9) of the Securities Act, involving an exchange of securities exchanged by the issuer with its existing security holders exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange. No underwriters were involved in this issuance of shares.

    All of the foregoing securities are deemed restricted securities for purposes of the Securities Act. All certificates representing the issued shares of capital stock described in this Item 15 included appropriate legends setting forth that the securities had not been registered and the applicable restrictions on transfer.

    Item 16. Exhibits and Financial Statement Schedules.

     

      (c)  

    Exhibits. See Exhibit Index attached to this registration statement, which is incorporated by reference herein.

     

      (d)  

    Financial Statement Schedules. Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes incorporated by reference into the prospectus forming a part of this registration statement.

    Item 17. Undertakings.

    The undersigned registrant hereby undertakes to provide to the underwriters, at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-3


    The undersigned hereby undertakes that:

     

      (1)

    For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

     

      (2)

    For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    II-4


    Exhibit Index

     

    Exhibit
    Number
      

    Exhibit Description

       Incorporated by Reference      Filed
    Herewith
     
              Form      Date      Number         
     1.1    Form of Underwriting Agreement               X  
     3.1    Amended and Restated Certificate of Incorporation      S-1/A        01/18/24        3.3     
     3.2    Amended and Restated Bylaws      S-1        01/02/24        3.4     
     4.1    Specimen stock certificate evidencing the shares of common stock      S-1/A        01/18/24        4.1     
     4.2    Amended and Restated Investors’ Rights Agreement, dated July  28, 2023, as amended, by and among the Registrant and certain of its stockholders      S-1/A        01/18/24        4.2     
     5.1    Opinion of Cooley LLP               X  
    10.1#    CG Oncology, Inc. 2015 Equity Incentive Plan, as amended, and form of stock grant agreement and form of stock option agreement thereunder      S-8        01/26/24        10.1     
    10.2#    CG Oncology, Inc. 2022 Incentive Award Plan and form of stock option agreement, form of stock option agreement (early exercise) and form of restricted stock unit agreement thereunder      S-8        01/26/24        10.2     
    10.3#    CG Oncology, Inc. 2024 Incentive Award Plan and form of stock option agreement and form of restricted stock unit agreement thereunder      S-8        01/26/24        10.3     
    10.4#    CG Oncology, Inc. 2024 Employee Stock Purchase Plan      S-8        01/26/24        10.4     
    10.5#    Non-Employee Director Compensation Program      S-1/A        01/18/24        10.5     
    10.6†    Development and License Agreement, dated March 11, 2019, between the Lepu Biotech Co., Ltd. and the Registrant      S-1        01/02/24        10.6     
    10.7†    License and Collaboration Agreement, dated March 26, 2020, between Kissei Pharmaceutical Co., Ltd. and the Registrant      S-1        01/02/24        10.7     
    10.8†    First Amendment to the License and Collaboration Agreement, dated September  15, 2022, between Kissei Pharmaceutical Co., Ltd. and the Registrant      S-1        01/02/24        10.8     
    10.9#    Form of Indemnification Agreement for Directors and Officers      S-1        01/02/24        10.9     
    10.10#    CG Oncology, Inc. Annual Bonus Plan      S-1        01/02/24        10.11     
    10.11#    Amended and Restated Employment Agreement, effective March 15, 2023, between Arthur Kuan and the Registrant      S-1        01/02/24        10.12     
    10.12#    Amended and Restated Employment Agreement, effective December 13, 2023, between Arthur Kuan and the Registrant      S-1        01/02/24        10.13     

     

    II-5


    Exhibit
    Number
      

    Exhibit Description

       Incorporated by Reference      Filed
    Herewith
     
              Form      Date      Number         
    10.13#    Employment Agreement, effective July 9, 2023, between Ambaw Bellete and the Registrant      S-1        01/02/24        10.14     
    10.14#    Amended and Restated Employment Agreement, effective December 13, 2023, between Ambaw Bellete and the Registrant      S-1        01/02/24        10.15     
    10.15#    Employment Agreement, effective August 14, 2023, between Vijay Kasturi and the Registrant      S-1        01/02/24        10.16     
    10.16#    Amended and Restated Employment Agreement, effective December 13, 2023, between Vijay Kasturi and the Registrant      S-1        01/02/24        10.17     
    10.17#    Employment Agreement, effective January 16, 2024, between Corleen Roche and the Registrant      S-1/A        01/18/24        10.18     
    23.1*    Consent of Independent Registered Public Accounting Firm            
    23.2    Consent of Cooley LLP (included in Exhibit 5.1)               X  
    24.1*    Power of Attorney (included on signature page)            
    107*    Filing Fee Table            

     

    *

    Previously filed.

    #

    Indicates management contract or compensatory plan.

    †

    Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601 of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential.

     

    II-6


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on this 11th day of December, 2024.

     

    CG ONCOLOGY, INC.

    By:

     

    /s/ Arthur Kuan

       

    Arthur Kuan

       

    Chairman and Chief Executive Officer

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

     

    Signature

     

    Title

     

    Date

    /s/ Arthur Kuan

    Arthur Kuan

     

    Chairman and Chief Executive Officer

    (principal executive officer)

      December 11, 2024

    /s/ Corleen Roche

    Corleen Roche

     

    Chief Financial Officer

    (principal financial and accounting officer)

      December 11, 2024

    *

    Susan Graf

     

    Director

      December 11, 2024

    *

    Brian Liu, M.D.

     

    Director

      December 11, 2024

    *

    James J. Mulé, IPh.D.

     

    Director

      December 11, 2024

    *

    Leonard Post, Ph.D.

     

    Director

      December 11, 2024

    *

    Simone Song

     

    Director

      December 11, 2024

    *

    Victor Tong, Jr.

     

    Director

      December 11, 2024
    By:   /s/ Arthur Kuan       
      Arthur Kuan       
      Attorney-in-Fact       

     

    II-7

    Get the next $CGON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGON

    DatePrice TargetRatingAnalyst
    12/11/2025$70.00Outperform
    Wedbush
    11/24/2025Buy
    Truist
    10/8/2025$90.00Buy
    Guggenheim
    8/19/2025$55.00Overweight
    Piper Sandler
    7/10/2025$40.00Buy
    Goldman
    5/2/2025$41.00Overweight
    Analyst
    4/16/2025$23.00Sector Perform
    Scotiabank
    1/7/2025Buy
    TD Cowen
    More analyst ratings

    $CGON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Liu Brian Guan-Chyun bought $49,999,983 worth of shares (1,515,151 units at $33.00) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/15/25 8:32:19 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Decheng Capital Global Life Sciences Fund Iv, L.P. bought $7,600,000 worth of shares (400,000 units at $19.00) (SEC Form 4) (Amendment)

    4/A - CG Oncology, Inc. (0001991792) (Issuer)

    4/9/24 7:08:23 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

    SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br

    1/14/26 9:00:00 AM ET
    $CGON
    $ONCY
    $TAK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 12, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as genomics in cancer care expands toward a projected $69.16 billion by 2032[1]. This massive growth is driven by the systematic integration of genotype-directed treatment pathways into standard medical practice. The precision medicine market is now on a trajectory to expand from $138.67 billion in 2026 to over $537.17 billion by 2035[2]. This strategic pivot toward registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), CG Oncology (NASDAQ:CGON), Ze

    1/12/26 10:35:00 AM ET
    $AVBP
    $CGON
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

    - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC IRVINE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced an expedited timeline for the topline data readout now expected in the first half of 2026 for the Phase 3 PIVOT-006 clinical trial comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). PIVOT-006 is the first Phase 3 randomi

    1/9/26 8:30:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    SEC Filings

    View All

    SEC Form 8-K filed by CG Oncology Inc.

    8-K - CG Oncology, Inc. (0001991792) (Filer)

    1/13/26 4:51:58 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by CG Oncology Inc.

    424B5 - CG Oncology, Inc. (0001991792) (Filer)

    1/13/26 4:47:48 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by CG Oncology Inc.

    144 - CG Oncology, Inc. (0001991792) (Subject)

    1/9/26 4:32:41 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on CG Oncology with a new price target

    Wedbush initiated coverage of CG Oncology with a rating of Outperform and set a new price target of $70.00

    12/11/25 8:19:48 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on CG Oncology

    Truist initiated coverage of CG Oncology with a rating of Buy

    11/24/25 8:30:31 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on CG Oncology with a new price target

    Guggenheim initiated coverage of CG Oncology with a rating of Buy and set a new price target of $90.00

    10/8/25 8:32:13 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mulay James sold $584,799 worth of shares (11,145 units at $52.47) and exercised 11,145 shares at a strike of $12.07 (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    1/13/26 4:15:07 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Rossi Christina

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    11/26/25 4:30:09 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Rossi Christina

    3 - CG Oncology, Inc. (0001991792) (Issuer)

    11/26/25 4:15:03 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Financials

    Live finance-specific insights

    View All

    CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

    - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events or deaths reported – - Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – - Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 - IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:C

    4/26/25 4:10:03 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

    IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on

    4/24/25 8:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

    - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS

    3/28/25 7:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Leadership Updates

    Live Leadership Updates

    View All

    Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

    SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br

    1/14/26 9:00:00 AM ET
    $CGON
    $ONCY
    $TAK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CG Oncology Announces New Board Member and Board Transition

    - Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the appointment of Christina Rossi to its Board of Directors. Additionally, Simone Song, Senior Partner, ORI Capital, has resigned from the Board effective November 22, 2025. "We are at a critical juncture in CG Oncology's history with our recent BLA initiation for cretostimogene. Now we are laying the foundation for a successful

    11/26/25 7:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

    6/18/25 11:19:00 AM ET
    $CATX
    $CGON
    $GALT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $CGON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

    SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

    11/12/24 2:30:47 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

    SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

    11/4/24 10:22:51 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by CG Oncology Inc.

    SC 13G - CG Oncology, Inc. (0001991792) (Subject)

    7/22/24 4:35:57 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care